118 related articles for article (PubMed ID: 6115572)
21. Hemodynamic and clinical effects of a new inotropic agent TA-064 in patients with refractory heart failure due to cardiomyopathy with special reference to dose-response effects.
Matsumoto N; Matsumura K; Takahashi S; Kimata S; Hirosawa K
Heart Vessels Suppl; 1985; 1():187-94. PubMed ID: 3843582
[TBL] [Abstract][Full Text] [Related]
22. Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.
Pamelia FX; Gheorghiade M; Beller GA; Bishop HL; Olukotun AY; Taylor CR; Watson DD; Grunwald AM; Sirowatka J; Carabello BA
Am Heart J; 1983 Dec; 106(6):1369-76. PubMed ID: 6359846
[TBL] [Abstract][Full Text] [Related]
23. Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure.
Amin DK; Shah PK; Hulse S; Shellock F
Am Heart J; 1985 May; 109(5 Pt 1):1006-12. PubMed ID: 3158182
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular effects of a newly synthesized cardiotonic agent (TA-064) on normal and diseased hearts.
Kino M; Hirota Y; Yamamoto S; Sawada K; Moriguchi M; Kotaka M; Kubo S; Kawamura K
Am J Cardiol; 1983 Mar; 51(5):802-10. PubMed ID: 6829441
[TBL] [Abstract][Full Text] [Related]
25. CI-930, a new cardiotonic and vasodilating agent: hemodynamic comparison to dobutamine and long-term clinical effects.
Mancini D; Keren G; Sonnenblick EH; LeJemtel TH
Am Heart J; 1988 Oct; 116(4):1008-16. PubMed ID: 3177174
[TBL] [Abstract][Full Text] [Related]
26. Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol.
Ence TJ; Tashkin DP; Ho D; Child JS
Ann Allergy; 1979 Oct; 43(4):229-36. PubMed ID: 555600
[TBL] [Abstract][Full Text] [Related]
27. Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure.
Canepa-Anson R; Dawson JR; Kuan P; Poole-Wilson PA; Sutton GC; Cockrill B; Reuben SR
Br J Clin Pharmacol; 1987 Feb; 23(2):173-81. PubMed ID: 3828194
[TBL] [Abstract][Full Text] [Related]
28. Use of a hand-held, metered-dose aerosol delivery device to administer pirbuterol acetate to horses with 'heaves'.
Derksen FJ; Olszewski M; Robinson NE; Berney C; Lloyd JW; Hakala J; Matson C; Ruth D
Equine Vet J; 1996 Jul; 28(4):306-10. PubMed ID: 8818596
[TBL] [Abstract][Full Text] [Related]
29. Intravenous pirbuterol.
Leier CV; Nelson S; Huss P; Bianchine JR; Olukotun AY; Taylor CR; Salzburg DS
Clin Pharmacol Ther; 1982 Jan; 31(1):89-94. PubMed ID: 7053311
[TBL] [Abstract][Full Text] [Related]
30. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
[TBL] [Abstract][Full Text] [Related]
31. Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta-2 adrenoreceptors (dopexamine) in patients with heart failure.
Jamison M; Widerhorn J; Weber L; Campese V; Vasquez J; Hovanessian L; Rahimtoola SH; Elkayam U
Am Heart J; 1989 Mar; 117(3):607-14. PubMed ID: 2537556
[TBL] [Abstract][Full Text] [Related]
32. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
[TBL] [Abstract][Full Text] [Related]
33. Comparison of hemodynamic actions of pirbuterol and dobutamine on cardiac function in severe congestive heart failure.
Awan NA; Needham KE; Evenson MK; Mason DT
Am J Cardiol; 1981 Mar; 47(3):665-9. PubMed ID: 7468500
[No Abstract] [Full Text] [Related]
34. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study.
Gilbert EM; Bristow MR; Mason JW
Am J Cardiol; 1987 Aug; 60(5):57C-62C. PubMed ID: 2956870
[TBL] [Abstract][Full Text] [Related]
35. Preload-dependent hemodynamic effects of milrinone in moderate heart failure.
Remme WJ; van Hoogenhuyze DC; Kruijssen HA; Pieper PG; Bruggeling WA
Cardiology; 1992; 80(2):132-42. PubMed ID: 1611632
[TBL] [Abstract][Full Text] [Related]
36. Hemodynamic action of nicorandil in chronic congestive heart failure.
Solal AC; Jaeger P; Bouthier J; Juliard JM; Dahan M; Gourgon R
Am J Cardiol; 1989 Jun; 63(21):44J-48J. PubMed ID: 2525325
[TBL] [Abstract][Full Text] [Related]
37. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent.
Renard M; Walter M; Liebens I; Dresse A; Bernard R
Chest; 1988 Jun; 93(6):1159-64. PubMed ID: 3371093
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic effects of oral nicorandil in congestive heart failure.
Tice FD; Binkley PF; Cody RJ; Moeschberger ML; Mohrland JS; Wolf DL; Leier CV
Am J Cardiol; 1990 Jun; 65(20):1361-7. PubMed ID: 2140489
[TBL] [Abstract][Full Text] [Related]
39. Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy.
Jafri SM; Burlew BS; Goldberg AD; Olson S; Froelich JW; Goldstein S
Am J Cardiol; 1987 May; 59(12):1126-30. PubMed ID: 3578054
[TBL] [Abstract][Full Text] [Related]
40. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
DasGupta P; Broadhurst P; Lahiri A
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
